The mRNA encoding TAFI is alternatively spliced in different cell types and produces intracellular forms of the protein lacking TAFIa activity

Summary

TAFI (thrombin-activatable fibrinolysis inhibitor) is a pro-carboxypeptidase, encoded by the CPB2 gene in humans that links the coagulation cascade to fibrinolysis and inflammation. The liver is the main source for plasma TAFI, and TAFI expression has been documented in platelets and monocyte-derived macrophages. A recent study reported an alternatively spliced CPB2 mRNA variant lacking exon 7 (Δ7) in HepG2 cells and liver. Another study identified a CPB2 mRNA variant lacking exon 7 and a 52 bp deletion in exon 11 (Δ7+11) in human hippocampus. We have examined alternative splicing of CPB2 mRNA in various cell types by RT-PCR and have assessed the functional properties of TAFI variants encoded by these transcripts by recombinant expression in mammalian cells. We identified the Δ7 exon skipping event in liver, Dami megakaryoblasts, THP-1-derived macrophages, peripheral blood mononuclear cells, platelets, testis, cerebellum, and SH-SY5Y neuroblastoma cells. The Δ11 alternative splicing event was notably absent in liver cells. We also detected a novel exon Δ7+8 skipping event in liver and megakaryocytes. Of note, we detected non-alternatively spliced CPB2 transcripts in brain tissues, suggesting the expression of full-length TAFI in brain. Experiments using cultured mammalian cells transfected with wild-type CPB2-, Δ7-, Δ7+11 -, and_Δ11 -cDNA revealed that alternatively spliced TAFI is stored inside the cells, cannot be activated by thrombin-thrombomodulin, and does not have TAFIa activity. The alternative splicing events clearly do not give rise to a secreted protein with basic carboxy-peptidase activity, but the intracellular forms may possess novel functions related to intracellular proteolysis.

Keywords

Thrombin-activatable fibrinolysis inhibitor (TAFI) - alternative splicing - liver - brain - monocytes/macrophages - megakaryocytes

• References

• 1 Marx PF, Verkleij CJ, Valls Seron M. et al. Recent developments in thrombin-activatable fibrinolysis inhibitor research. Mini Rev Med Chem 2009; 09: 1165-1173.
• 2 Leung LL, Nishimura T, Myles T. Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI). Adv Exp Med Biol 2008; 632: 61-69.
• 3 Eaton DL, Malloy BE, Tsai SP. et al. Isolation, molecular cloning, and partial characterisation of a novel carboxypeptidase B from human plasma. J Biol Chem 1991; 266: 21833-21838.
• 4 Bajzar L, Manuel R, Nesheim ME. Purification and characterisation of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-14484.
• 5 Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271: 16603-16608.
• 6 Mao SS, Cooper CM, Wood T. et al. Characterisation of plasmin-mediated activation of plasma procarboxypeptidase B. Modulation by glycosaminoglycans. J Biol Chem 1999; 274: 35046-35052.
• 7 Vanhoof G, Wauters J, Schatteman K. et al. The gene for human carboxypeptidase U (CPU)--a proposed novel regulator of plasminogen activation--maps to 13q14.11. Genomics 1996; 38: 454-455.
• 8 Boffa MB, Reid TS, Joo E. et al. Characterisation of the gene encoding human TAFI (thrombin-activable fibrinolysis inhibitor; plasma procarboxypeptidase B). Biochemistry 1999; 38: 6547-6558.
• 9 Van Thiel DH, George M, Fareed J. Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease. Thromb Haemost 2001; 85: 667-670.
• 10 Mosnier LO, Buijtenhuijs P, Marx PF. et al. Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets. Blood 2003; 101: 4844-4846.
• 11 Schadinger SL, Lin JH, Garand M. et al. Secretion and antifibrinolytic function of thrombin-activatable fibrinolysis inhibitor from human platelets. J Thromb Haemost 2010; 08: 2523-2529.
• 12 Lin JH, Garand M, Zagorac B. et al. Identification of human thrombin-activatable fibrinolysis inhibitor in vascular and inflammatory cells. Thromb Haemost 2011; 105: 999-1009.
• 13 Hori Y, Gabazza EC, Yano Y. et al. Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 660-665.
• 14 Matsumoto A, Itoh K, Matsumoto R. A novel carboxypeptidase B that processes native beta-amyloid precursor protein is present in human hippocampus. Eur J Neurosci 2000; 12: 227-238.
• 15 Matsumoto A, Itoh K, Seki T. et al. Human brain carboxypeptidase B, which cleaves beta-amyloid peptides in vitro, is expressed in the endoplasmic reticulum of neurons. Eur J Neurosci 2001; 13: 1653-1657.
• 16 Matsumoto A, Motozaki K, Seki T. et al. Expression of human brain carboxy-peptidase B, a possible cleaving enzyme for beta-amyloid precursor protein, in peripheral fluids. Neurosci Res 2001; 39: 313-317.
• 17 Cagliani R, Fumagalli M, Riva S. et al. Polymorphisms in the CPB2 gene are maintained by balancing selection and result in haplotype-preferential splicing of exon 7. Mol Biol Evol 2010; 27: 1945-1954.
• 18 Boffa MB, Wang W, Bajzar L. et al. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties. J Biol Chem 1998; 273: 2127-2135.
• 19 Peng SS, Chen CY, Shyu AB. Functional characterisation of a non-AUUUA AU-rish element from the c-jun proto-oncogene mRNA: evidence for a novel class of AU-rich elements. Mol Cell Biol 1996; 16: 1490-1499.
• 20 Kim PY, Foley J, Hsu G. et al. An assay for measuring functional activated thrombin-activatable fibrinolysis inhibitor in plasma. Anal Biochem 2008; 372: 32-40.
• 21 Pan Q, Shai O, Lee LJ. et al. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 2008; 40: 1413-1415.
• 22 Sorek R, Shamir R, Ast G. How prevalent is functional alternative splicing in the human genome?. Trends Genet 2004; 20: 68-71.
• 23 Melamud E, Moult J. Stochastic noise in splicing machinery. Nucleic Acids Res 2009; 37: 4873-4886.
• 24 Asselta R, Rimoldi V, Guella I. et al. Molecular characterisation of in-frame and out-of-frame alternative splicings in coagulation factor XI pre-mRNA. Blood 2010; 115: 2065-2072.
• 25 Denis MM, Tolley ND, Bunting M. et al. Escaping the nuclear confines: signal-dependent pre-mRNA splicing in anucleate platelets. Cell 2005; 122: 379-391.
• 26 Carter MS, Doskow J, Morris P. et al. A regulatory mechanism that detects premature nonsense codons in T-cell receptor transcripts in vivo is reversed by protein synthesis inhibitors in vitro. J Biol Chem 1995; 270: 28995-29003.
• 27 Pan Q, Saltzman AL, Kim YK. et al. Quantitative microarray profiling provides evidence against widespread coupling of alternative splicing with nonsense-mediated mRNA decay to control gene expression. Genes Dev 2006; 20: 153-158.
• 28 Boffa MB, Nesheim ME, Koschinsky ML. Thrombin activable fibrinolysis inhibitor (TAFI): molecular genetics of an emerging potential risk factor for thrombotic disorders. Curr Drug Targets Cardiovasc Haematol Disord 2001; 01: 59-74.
• 29 Marx PF, Brondijk TH, Plug T. et al. Crystal structures of TAFI elucidate the in-activation mechanism of activated TAFI: a novel mechanism for enzyme autoregulation. Blood 2008; 112: 2803-2809.
• 30 Henry M, Aubert H, Morange PE. et al. Identification of polymorphisms in the promoter and the 3’ region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood 2001; 97: 2053-2058.
• 31 Melchor JP, Strickland S. Tissue plasminogen activator in central nervous system physiology and pathology. Thromb Haemost 2005; 93: 655-660.
• 32 Porollo A, Meller J. Versatile Annotation and Publication Quality Visualization of Protein Complexes Using POLYVIEW-3D. BMC Bioinformatics 2007; 08: 316.